A practical guide to the recognition and management of myasthenia gravis

Drugs

Volumn 52, Issue 5, 1996, Pages 662-670

  Evoli, Amelia ^a   Batocchi, Anna Paola ^a   Tonali, Pietro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NEOSTIGMINE; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE;

ANEMIA; ANTIBODY TITER; AUTOIMMUNITY; CARCINOGENESIS; CATARACT; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSIS; DIARRHEA; DRUG THERAPY; ELECTROMYOGRAM; EXTRAOCULAR MUSCLE; FASCICULATION; HUMAN; HYPERSALIVATION; HYPERTENSION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LACRIMATION; MOON FACE; MUSCLE FATIGUE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; REMISSION; REVIEW; SIDE EFFECT; SURGERY; SWEATING; TERATOGENICITY; THYMECTOMY; WEIGHT GAIN;

EID: 0029802474     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00004     Document Type: Review

References (39)

1. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984; 16: 519-34
2. Evoli A, Tonali P, Bartoccioni E, et al. Ocular myasthenia gravis: diagnostic and therapeutic problems. Acta Neurol Scand 1988; 77: 31-5
3. Newsom-Davis J, Willcox N, Schluep M, et al. Immunologic heterogeneity and cellular mechanisms in myasthenia gravis. Ann NY Acad Sci 1987; 505: 12-26
4. Oosterhuis HJGH. Myasthenia gravis: clinical neurology and neurosurgery monographs. Edinburgh: Churchill Livingstone, 1984
5. Oh SJ, Cho HK. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis. Muscle Nerve 1990; 13: 187-91
6. Phillips LH, Melnick PA. Diagnosis of myasthenia gravis in the 1990s. Semin Neurol 1990; 10: 62-9
7. Howard JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994; 12 (2): 305-30
8. Sanders DB, Howard JT. AAEE minimograph no. 25: single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986; 9: 809-19
9. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977; 7: 36-43
10. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246-52
11. Limburg PC, The TH, Hummel-Tappel E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis: pt 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983; 58: 357-70
12. Engel AG. Congenital myasthenic syndromes. Neurol Clin 1994; 12 (2): 401-37
13. Vincent A, Li Z, Hart A, et al. Seronegative myasthenia gravis: evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann NY Acad Sci 1993; 681: 529-38
14. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-810
15. Sanders DB, Scoppetta C. The treatment of patients with myasthenia gravis. Neurol Clin 1994; 12 (2): 343-68
16. Ricciardi R, Rossi B, Nicora M, et al. Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation. J Neurol Neurosurg Psychiatry 1991; 54: 1061-2
17. Abramsky O, Aharonov A, Teitelbaum D, et al. Myasthenia gravis and acetylcholine receptor: effect of steroids on clinical course and cellular immune response to AChR. Arch Neurol 1975; 32: 684-7
18. Tindall RSA. Humoral autoimmunity in myasthenia gravis: effects of steroids and thymectomy. Neurology 1980; 30: 554-7
19. Sommer N, Melms A, Weller M, et al. Ocular myasthenia gravis: a critical review of clinical and pathophysiological aspects. Doc Ophtalm 1993; 84: 309-33
20. Haward CWH, Fonseca V. New treatment approaches to myasthenia gravis. Drugs 1990; 39: 66-73
21. Johns TR. Long-term corticosteroid treatment in myasthenia gravis. Ann NY Acad Sci 1987; 505: 568-83
22. Evoli A, Batocchi AP, Pulmisani MT, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37-43
23. Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17: 238-42
24. Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann NY Acad Sci 1987; 505: 589-94
25. Osterman PO. Current treatment of myasthenia gravis. Prog Brain Res 1990; 84: 151-61
26. Hohlfeld R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258-61
27. Niakan E, Harati Y, Rolak LA. Immunosuppressive drug therapy in myasthenia gravis. Arch Neurol 1988; 43: 155-6
28. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK 506 and cyclosporine A. Ann NY Acad Sci 1993 Nov 30; 696: 9-19
29. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993 Jun 21; 681: 539-51
30. Perlo VP, Shahani BT, Huggins CE, et al. Effect of plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1981; 377: 709-24
31. Tindall RSA. Plasmapheresis for neurologic disorders. Curr Neurol 1990; 10: 177-93
32. Heininger K, Hartung HP, Toyka KV, et al. Therapeutic plasma exchange in myasthenia gravis: selective adsorption of anti-AChR autoantibodies with tryptophane-linked polyvinyl-alcohol gels. Ann NY Acad Sci 1987; 505: 898-900
33. Antozzi C, Berta E, Confalonieri P, et al. Protein A immunoadsorption in immunosuppression-resistant myasthenia gravis. Lancet 1994; 343: 124
34. Cosi V, Lombardi M, Piccolo G, et al. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84: 81-4
35. Arsura EL, Bick A, Brunner NG, et al. High dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986; 146: 1365-8
36. Evoli A, Palmisani MT, Bartoccioni E, et al. High-dose intravenous immunoglobulin in myasthenia gravis. Ital J Neurol Sci 1993; 14: 233-7
37. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-9
38. Ahlberg R, Yi Q, Pirskanen R, et al. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody. Ann NY Acad Sci 1993; 681: 552-5
39. Donaldson DH, Ansher M, Rutherford RB, et al. The relationship of age to outcome in myasthenia gravis. Neurology 1990; 40: 786-90